Top Markets
Coin of the day
Kyverna Therapeutics, Inc. Kyverna Therapeutics, Inc.

Kyverna Therapeutics, Inc.

KYTX
주식 순위 #13175
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses... Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
주가
$8.46
마지막 동기화: 2026-08-28
시가총액
$514.33M
변동 (1일)
-2.08%
변동 (1년)
128.03%
국가
US
거래 Kyverna Therapeutics, Inc. (KYTX)

카테고리

Kyverna Therapeutics, Inc. (KYTX)의 주식 분할 이력
Kyverna Therapeutics, Inc. 주식 (심볼: KYTX)은 총 0회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 31, 2026에 발생했습니다.
Aug 31, 2026 이전에 매수한 KYTX 주식 1주는 현재 0주의 KYTX 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
NL
1 x3
AU
0 -
US
0 -
CH